TGA grants provisional approval to Gilead Sciences Pty Ltd to extend the use of the COVID-19 treatment, VEKLURY (remdesivir)
Published
Related content
-
COVID-19 treatment: Gilead Sciences Pty Ltd, remdesivir (VEKLURY)
On 10 July 2020 the Therapeutic Goods Administration (TGA) granted provisional approval to remdesivir ("Veklury", Gilead Sciences Pty Ltd) as the first treatment option for COVID-19 -
TGA approves provisional determination for Gilead Sciences Pty Ltd for COVID-19 treatment, VEKLURY (remdesivir), for proposed use in children and adults who are at risk of progressing to severe COVID-19
The TGA has granted a second provisional determination to Gilead Sciences Pty Ltd in relation to its COVID-19 treatment, VEKLURY (remdesivir). -
TGA provisionally approves AstraZeneca's combination therapy (tixagevimab and cilgavimab, EVUSHELD) - for treatment and pre-exposure prevention (prophylaxis) of COVID-19
The TGA has granted provisional approval to AstraZeneca Pty Ltd for its tixagevimab and cilgavimab (EVUSHELD) for the treatment and prevention of COVID-19 in people who are at risk of infection but have not been exposed to the virus, known as pre-exposure prevention of COVID-19.